Last reviewed · How we verify

Tislelizumab, Carboplatin, Paxlitaxel

Akeso · Phase 3 active Small molecule

Tislelizumab, Carboplatin, Paxlitaxel is a PD-1 inhibitor Small molecule drug developed by Akeso. It is currently in Phase 3 development for Metastatic non-small cell lung cancer, PD-L1 positive, Esophageal squamous cell carcinoma, Hepatocellular carcinoma.

Tislelizumab is a monoclonal antibody that targets PD-1, a protein on the surface of T cells that helps to regulate the immune response. By binding to PD-1, tislelizumab blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, which are expressed on tumor cells and other cells in the tumor microenvironment. This blockade enhances the immune response against cancer cells.

Tislelizumab is a monoclonal antibody that targets PD-1, a protein on the surface of T cells that helps to regulate the immune response. By binding to PD-1, tislelizumab blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, which are expressed on tumor cells and other cells in the tumor microenvironment. This blockade enhances the immune response against cancer cells. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Esophageal squamous cell carcinoma, Hepatocellular carcinoma.

At a glance

Generic nameTislelizumab, Carboplatin, Paxlitaxel
SponsorAkeso
Drug classPD-1 inhibitor
TargetPD-1
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Tislelizumab is a PD-1 inhibitor, which means it works by blocking the PD-1/PD-L1 axis. This blockade allows the immune system to recognize and attack cancer cells more effectively. Tislelizumab has been shown to be effective in treating various types of cancer, including non-small cell lung cancer, esophageal squamous cell carcinoma, and hepatocellular carcinoma.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Tislelizumab, Carboplatin, Paxlitaxel

What is Tislelizumab, Carboplatin, Paxlitaxel?

Tislelizumab, Carboplatin, Paxlitaxel is a PD-1 inhibitor drug developed by Akeso, indicated for Metastatic non-small cell lung cancer, PD-L1 positive, Esophageal squamous cell carcinoma, Hepatocellular carcinoma.

How does Tislelizumab, Carboplatin, Paxlitaxel work?

Tislelizumab is a monoclonal antibody that targets PD-1, a protein on the surface of T cells that helps to regulate the immune response. By binding to PD-1, tislelizumab blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, which are expressed on tumor cells and other cells in the tumor microenvironment. This blockade enhances the immune response against cancer cells.

What is Tislelizumab, Carboplatin, Paxlitaxel used for?

Tislelizumab, Carboplatin, Paxlitaxel is indicated for Metastatic non-small cell lung cancer, PD-L1 positive, Esophageal squamous cell carcinoma, Hepatocellular carcinoma.

Who makes Tislelizumab, Carboplatin, Paxlitaxel?

Tislelizumab, Carboplatin, Paxlitaxel is developed by Akeso (see full Akeso pipeline at /company/akeso).

What drug class is Tislelizumab, Carboplatin, Paxlitaxel in?

Tislelizumab, Carboplatin, Paxlitaxel belongs to the PD-1 inhibitor class. See all PD-1 inhibitor drugs at /class/pd-1-inhibitor.

What development phase is Tislelizumab, Carboplatin, Paxlitaxel in?

Tislelizumab, Carboplatin, Paxlitaxel is in Phase 3.

What are the side effects of Tislelizumab, Carboplatin, Paxlitaxel?

Common side effects of Tislelizumab, Carboplatin, Paxlitaxel include Fatigue, Nausea, Diarrhea, Rash, Pyrexia.

What does Tislelizumab, Carboplatin, Paxlitaxel target?

Tislelizumab, Carboplatin, Paxlitaxel targets PD-1 and is a PD-1 inhibitor.

Related